BioCardia (BCDA) Cash from Operations Growth (1y) (2011 - 2026)
Powered by 
Analysis
BioCardia (BCDA) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.23 Bn | 9.39 Bn | 112.79 Mn | 41.84% |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.67 Bn | 3.37 Bn | 55.72 Mn | 9.83% |
| 4 | Legend Biotech | 3.55 Bn | 2.58 Bn | 251.50 Mn | -58.33% |
| 5 | uniQure | 3.00 Bn | 3.00 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - | - |
| 7 | Precigen | 2.36 Bn | 2.36 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.36 Bn | 251.87 Mn | -24.59% |
| 9 | Vericel | 1.95 Bn | 1.79 Bn | 56.40 Mn | 97.11% |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - | -5.22% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.22% |
| Mar 31, 2026 | -2.53% |
| Dec 31, 2025 | -2.63% |
| Sep 30, 2025 | 35.96% |
| Jun 30, 2025 | -25.69% |
| Mar 31, 2025 | -5.75% |
| Dec 31, 2024 | -31.44% |
| Sep 30, 2024 | -8.25% |
| Jun 30, 2024 | 58.36% |
| Mar 31, 2024 | 40.23% |
| Dec 31, 2023 | 38.24% |
| Sep 30, 2023 | -20.24% |
| Jun 30, 2023 | -19.13% |
| Mar 31, 2023 | 12.12% |
| Dec 31, 2022 | -0.74% |
| Sep 30, 2022 | 24.10% |
| Jun 30, 2022 | 7.68% |
| Mar 31, 2022 | -54.70% |
| Dec 31, 2021 | 12.94% |
| Sep 30, 2021 | 26.66% |